EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 3.0

MAFLD: How is it different from NAFLD?

Cameron Gofton, Yadhavan Upendran, Ming-Hua Zheng, Jacob George

Clinical and Molecular Hepatology · 28.02.2023 · 29 (Suppl) · S17-S31

DOI: 10.3350/cmh.2022.0367 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 28.02.2023. Verfasst von Cameron Gofton und 3 weiteren Autor:innen. Beteiligte Einrichtung: Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Westmead, NSW, Australia. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Metabolic Diseases. Die Arbeit wurde bisher 423-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

“Metabolic dysfunction-associated fatty liver disease (MAFLD)” is the term suggested in 2020 to refer to fatty liver disease related to systemic metabolic dysregulation. The name change from nonalcoholic fatty liver disease (NAFLD) to MAFLD comes with a simple set of criteria to enable easy diagnosis at the bedside for the general medical community, including primary care physicians. Since the introduction of the term, there have been key areas in which the superiority of MAFLD over the traditional NAFLD terminology has been demonstrated, including for the risk of liver and extrahepatic mortality, disease associations, and for identifying high-risk individuals. Additionally, MAFLD has been adopted by a number of leading pan-national and national societies due to its concise diagnostic criterion, removal of the requirement to exclude concomitant liver diseases, and reduction in the stigma associated with this condition. The current article explores the differences between MAFLD and NAFLD diagnosis, areas of benefit, some potential limitations, and how the MAFLD terminology has opened up new fields of research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseMetabolic DiseasesHumans

Stichwörter der Autor:innen

MAFLDMAFLD vs. NAFLDNAFLD

Autor:innen und Institutionen

  • Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Westmead, NSW, Australia.
  • Department of Gastroenterology and Hepatology, Royal North Shore Hospital, St Leonards, NSW, Australia.
  • Department of Gastroenterology and Hepatology, Bankstown-Lidcombe Hospital, Bankstown, NSW, Australia.
  • Department of Gastroenterology and Hepatology, University of New South Wales, Sydney, NSW, Australia.
  • MAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
  • Wenzhou Key Laboratory of Hepatology, Wenzhou, China.

Zitieren

APA

Gofton, C., Upendran, Y., Zheng, M. H., & George, J. (2023). MAFLD: How is it different from NAFLD?. Clinical and Molecular Hepatology, 29(Suppl), S17-S31. https://doi.org/10.3350/cmh.2022.0367

Vancouver

Gofton C, Upendran Y, Zheng MH, George J. MAFLD: How is it different from NAFLD?. Clinical and Molecular Hepatology. 2023;29(Suppl):S17-S31. doi:10.3350/cmh.2022.0367

BibTeX
@article{Gofton2023,
  author = {Gofton, Cameron and Upendran, Yadhavan and Zheng, Ming-Hua and George, Jacob},
  title = {MAFLD: How is it different from NAFLD?},
  journal = {Clinical and Molecular Hepatology},
  year = {2023},
  volume = {29},
  number = {Suppl},
  pages = {S17--S31},
  doi = {10.3350/cmh.2022.0367}
}
Kostenlos starten →